Kaneka Pharma Europe will present new applications for its flagship Kaneka QH ubiquinol form of CoQ10, as well as fat-burning Glavonoid licorice root extract.
At Health Ingredients Europe, Kaneka Pharma Europe will present new applications for its flagship Kaneka QH ubiquinol form of CoQ10. As a significant part of the respiratory chain inside mitochondrial cells, CoQ10 is important for energy production. Ubiquinol is the reduced form of CoQ10. Because it is already in its active form and does not have to be converted by the body, ubiquinol is effective more rapidly, the company explains. Additionally, the company will present thelicorice root extract Glavonoid, which the firm says helps reduce visceral fat. Glavonoid recently gained Novel Food statusfrom the European Commission. The polyphenols derived from licorice root (Glycyrrhiza glabra L.) have been discovered to ameliorate abdominal obesity and to target visceral fat in particular, thanks to a unique two-way efficiency profile:on one hand, it increases the body’s own fat-burning ability, and on the other hand, it decreases fat synthesis by down-regulating genes that are involved in fatty acid development, the company explains.